In a groundbreaking move, Profluent, a new startup emerging from research initiated by Salesforce, is leveraging the power of artificial intelligence (AI) to revolutionize how we discover and develop medicines. Founded by Ali Madani, a former Salesforce researcher, and Alexander Meeske, an assistant professor of microbiology, Profluent aims to harness generative AI to design proteins that can lead to the creation of customized treatments for a range of diseases.
The inception of Profluent was inspired by Salesforce’s project ProGen, which demonstrated the potential of generative AI in designing artificial proteins. While ProGen marked a significant academic achievement with its research published in Nature Biotech, it didn’t find a pathway to commercial application within Salesforce. Profluent seeks to change that, aiming to translate this cutting-edge research into practical solutions that pharmaceutical companies can utilize.
Ali Madani envisions reversing the traditional drug development process by starting with patients’ specific needs and therapeutic goals and then working backward to engineer precise treatments. This innovative approach is based on the understanding that AI can design proteins to perform specific tasks, like crafting sentences with words, which are essential for numerous bodily functions.
Proteins are chains of amino acids that play crucial roles in our body, from hormone production to tissue repair. Madani discovered that AI could interpret and manipulate the structure of proteins in a manner similar to language processing. This discovery opened the door to using generative AI to predict and design new proteins with unprecedented functions, a technique Profluent is eager to advance.
Furthermore, Profluent’s ambitions extend into gene editing, a field ripe for innovation, mainly genetic diseases that cannot be treated with naturally occurring proteins. The startup is poised to develop bespoke gene-editing tools optimized to address individual patients’ unique genetic makeup.
This initiative has precedent. The use of generative AI in biotechnology has been explored by notable entities such as Nvidia, Meta, and DeepMind’s AlphaFold, each making strides in protein prediction and the design of molecules for drug development. Profluent distinguishes itself by focusing on generating and refining gene-editing systems, aiming to produce genetic medicines in collaboration with partners, streamlining the path to regulatory approval.
The implications of Profluent’s work are profound. The traditional drug development process is notoriously lengthy and expensive, often taking over a decade and costing up to $2.8 billion to bring a new medicine to market. By leveraging AI, Profluent seeks to dramatically reduce these timeframes and costs, shifting from a paradigm of accidental discovery to one of intentional design.
Supported by a recent $35 million funding round led by Spark Capital and backed by industry giants like Jeff Dean, Google’s chief scientist, Profluent is on the cusp of making significant advancements. With a focus on expanding its AI models and forging strategic partnerships, the company is gearing up to challenge existing paradigms in medicine development.
As Profluent competes in a rapidly evolving landscape alongside other ambitious startups, its success could herald a new medical era of more effective and accessible treatments. This venture not only exemplifies the potential of AI to transform industries but also underscores a hopeful future where medical solutions are tailored to patients’ individual needs, significantly impacting global health.
Source: Techcrunch
Like this article? Keep up to date with AI news, apps, tools and get tips and tricks on how to improve with AI. Sign up to our Free AI Newsletter
Also, come check out our free AI training portal and community of business owners, entrepreneurs, executives and creators. Level up your business with AI ! New courses added weekly.
You can also follow us on X